Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis
Open accessAbstract
UNLABELLED: There is limited information on test performance for detecting cholangiocarcinoma in primary sclerosing cholangitis (PSC), particularly when used sequentially. This study aimed to characterize diagnostic performance of serum carbohydrate antigen 19-9 (CA 19-9), ultrasonography, computed tomography, magnetic resonance imaging, cholangiography, and biliary cytologic techniques for detecting cholangiocarcinoma in PSC. All consecutive patients with PSC were screened and followed for development of cholangiocarcinoma from 2000 through 2006. Of 230 patients, 23 developed cytopathologically confirmed cholangiocarcinoma with an annual incidence of 1.2%. The optimal cutoff value for serum CA 19-9 was 20 U/mL, which yielded a sensitivity of 78%, specificity of 67%, positive predictive value (PPV) of 23%, and negative predictive value (NPV) of 96%. Serum CA 19-9 combined with either ultrasonography, computed tomography, or magnetic resonance imaging provided a sensitivity of 91%, 100%, and 96%, specificity of 62%, 38%, and 37%, PPV of 23%, 22%, and 24%, and NPV of 98%, 100%, and 98%, respectively, if at least one method was positive. Subsequent cholangiographic examinations in these patients increased specificity to 69% and PPV to 42% while maintaining sensitivity of 91% and NPV of 96%. Following this group, conventional cytology, aneuploidy detection by digital imaging analysis, and aneusomy detection by fluorescence in situ hybridization in brushing samples of biliary strictures had a sensitivity of 50%, 57%, and 86%, specificity of 97%, 94%, and 83%, PPV of 86%, 89%, and 80%, and NPV of 83%, 74%, and 88%, respectively, for detecting cholangiocarcinoma. CONCLUSION: Tumor serology combined with cross-sectional liver imaging may be useful as a screening strategy and cholangiography with cytologic examination is helpful for the diagnosis of cholangiocarcinoma in patients with PSC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The sensitivity for CCA detection is higher for MRI/MRCP (89%) than for ultrasound (57%).
“The sensitivity for CCA detection is higher for MRI/MRCP (89%) than for ultrasound (57%).118”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 15 · Cited by 393
Research works printed but not linked: 1
- American Joint Committee on Cancer. AJCC Cancer Staging. New York: Springer-Verlag; 2005:1-150.
- Authors
- Charatcharoenwitthaya, P., Enders, F. B., Halling, K. C., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Lindor, Keith D.
- Venue
- Hepatology
- Published
- 2008-10
- Volume
- 48
- Issue
- 4
- Pages
- 1106-1117
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1968896691
- Cited by
- 393
- References
- 15
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 21 · 2023: 19 · 2022: 20 · 2021: 26 · 2020: 18 · 2019: 17 · 2018: 22 · 2017: 35 · 2016: 19 · 2015: 30 · 2014: 25 · 2013: 25 · 2012: 24
- FWCI
- 22.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mahidol University
- Faculty of Medicine Siriraj Hospital, Mahidol University
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- primary sclerosing cholangitis, CA19-9, serum tumor markers, biliary cytology, biliary strictures, cholangiography, magnetic resonance cholangiopancreatography, computed tomography, ultrasonography, fluorescence in situ hybridization, aneuploidy detection, cancer screening, diagnostic accuracy
- MeSH terms
- Adult, Aged, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Female, Humans, Liver, Male, Mass Screening, Middle Aged, Predictive Value of Tests, Radiography, Retrospective Studies, Sensitivity and Specificity, Biomarkers, Tumor, Ultrasonography, Cholangitis, Sclerosing, Cholangiocarcinoma, CA-19-9 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
